Tin tức & Cập nhật
Xem bài viết Sản phụ khoa
Xem

Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.

Anaemia a major indication for obstetric red cell transfusion in multiethnic population
Red cell transfusion at a high-volume tertiary hospital in Singapore has an incidence of 3.2 percent in a multiethnic obstetric population, according to a study. Anaemia during pregnancy is the most common reason for transfusion administration.

Can very low-risk breast cancer patients be spared from postop radiotherapy?
Adjuvant radiotherapy (RT) may be omitted in women with very low-risk breast cancer who have had breast conserving surgery (BCS) and have been receiving endocrine therapy, according to findings from the LUMINA study.

Diabetes, excess weight up risk of COVID-19 in pregnancy
Diabetes mellitus and overweight or obesity appear to increase susceptibility to COVID-19 among pregnant women, with insulin-dependent gestational diabetes mellitus being associated with the disease, according to data from INTERCOVID.

L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.

Diabetes status may influence long-term survival in metastatic breast cancer
Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.


